Manaka Katsunori, Makita Noriko, Iiri Taroh
Department of Endocrinology and Nephrology, The University of Tokyo School of Medicine, Tokyo 113-8655 Japan.
Endocr J. 2014;61(2):185-94. doi: 10.1507/endocrj.ej13-0419. Epub 2013 Dec 3.
An early thirties man diagnosed with Erdheim-Chester disease (ECD) was simultaneously disclosed to have hypogonadotropic hypogonadism, central adrenal insufficiency, and GH deficiency in addition to central diabetes insipidus (CDI). Pituitary magnetic resonance imaging (MRI) showed swelling in the stalk, enlargement of the anterior lobe with delayed enhancement, and loss of high intensity of the posterior lobe on T1-weighted images, suggesting of pituitary involvement of ECD. Three months after starting treatment with interferon α and zoledronic acid, polyuria and polydipsia were ameliorated without DDAVP, accompanied with improvement of MRI. Simultaneously technetium-99m bone scintigraphy showed improvement, accompanied with a relief of bone pain and high fever. In contrast, he developed secondary hypothyroidism with slight enlargement of anterior pituitary gland without relapse of CDI, suggesting of different responses to treatment with interferon α between anterior pituitary lobe and posterior one. So far he continues to be replaced with deficient hormone replacement therapy. As for bone pain, it remains to be controlled with the decreased levels of bone resorption marker with decreased abnormal uptake in bone scintigraphy although zoledronic acid was discontinued for osteonecrosis of the jaw. For four years, he has not showed new involvement at other organs besides bones and the pituitary. While CDI is known to be very common in ECD, improvement of CDI has been reported in a few cases. Other endocrine manifestations, especially with detailed endocrine status, have been also reported in limited cases. Thus we report this case and review the literature.
一名三十出头被诊断为厄德里希-切斯特病(ECD)的男性,除中枢性尿崩症(CDI)外,还同时被发现患有低促性腺激素性性腺功能减退、中枢性肾上腺功能不全和生长激素缺乏。垂体磁共振成像(MRI)显示垂体柄增粗,前叶增大伴强化延迟,T1加权像上后叶高信号消失,提示ECD累及垂体。在开始使用干扰素α和唑来膦酸治疗三个月后,多尿和多饮症状在未使用去氨加压素的情况下得到改善,同时MRI表现也有所改善。同时,锝-99m骨闪烁显像显示病情改善,骨痛和高热缓解。相比之下,他出现了继发性甲状腺功能减退,垂体前叶稍有增大,CDI未复发,提示垂体前叶和后叶对干扰素α治疗的反应不同。到目前为止,他继续接受激素替代治疗以补充缺乏的激素。至于骨痛,尽管因颌骨坏死停用了唑来膦酸,但随着骨吸收标志物水平降低和骨闪烁显像异常摄取减少,骨痛仍有待控制。四年来,除了骨骼和垂体外,他未出现其他器官的新病变。虽然已知CDI在ECD中非常常见,但已有少数病例报告CDI有所改善。其他内分泌表现,尤其是详细的内分泌状况,也仅有有限的病例报道。因此,我们报告该病例并复习文献。